When a company provides a "business strategy update" these days, the news usually includes a cutback of some kind, and Orchid BioSciences Inc. proved no exception, saying it is phasing out its single nucleotide polymorphism genotyping instruments and the related consumables in its life sciences unit. (BioWorld Today)
There may be some doubt about what's just "a bad headache" and what's a migraine, but those who suffer the latter are absolutely sure what they're feeling. Often, their initial clue is the dreaded "prodrome," a sense that the migraine is about to occur. Then begin the throbbing, pulsing pain and extreme sensitivity to light and sound, maybe with nausea and changes in vision, such as the appearance of auras. (BioWorld Financial Watch)
Pozen Inc.'s injected migraine drug, MT300, achieved its primary endpoint - sustained relief of pain - in its second pivotal trial and, although the drug did not do as well meeting secondary endpoints during the two hours after dosing, it showed statistical significance in providing relief of those symptoms on a sustained basis. (Bioworld Today)